ReviewAnnals of nutrition & metabolism2026
Carrageenan: Food Additive or Health Concern? A Comprehensive Review.
Review in Annals of nutrition & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCarrageenan, a sulfated polysaccharide extracted from red seaweeds, is widely used in the food, pharmaceutical, and cosmetic industries due to its gelling, thickening, and stabilizing properties. SUMMARY: Its widespread use in the Western diet and processed foods has raised scientific interest regarding its health effects. Evidence remains contradictory: some studies report antioxidant, antiviral, antitumor, and immunomodulatory benefits, whereas others suggest potential adverse outcomes, including impaired glucose metabolism, intestinal inflammation, and immune dysregulation. These effects appear to depend on carrageenan type, molecular weight, purity, dosage, and host-related factors. Regulatory bodies such as the FDA and EFSA generally consider carrageenan safe, although concerns remain regarding infant formulas and long-term exposure. KEY MESSAGES: Carrageenan cannot be uniformly classified as beneficial or harmful. Its biological effects are context-specific, and further well-designed clinical and mechanistic studies are needed to clarify dose-response relationships, safety in vulnerable populations, and implications for industry and public health nutrition.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.